SAN DIEGO & SALT LAKE CITY–(BUSINESS WIRE)–$MYGN #ClassAction–Shareholder rights law firm Robbins Arroyo LLP announces that a purchaser of Myriad Genetics, Inc. (NASDAQ: MYGN) filed a class action complaint for alleged violations of the Securities Exchange Act of 1934 between September 2, 2016 and August 13, 2019. Myriad Genetics is a molecular diagnostic company that develops and markets prognostic medicine tests. Myriad’s products include GeneSight, a DNA genotyping test that aids in psychotropic drug selection for depressed patients and ForeSight, a carrier screening test.
If you suffered a loss as a result of Myriad’s misconduct, click here.
Myriad Genetics, Inc. (MYGN) Accused of Misleading Shareholders
According to the complaint, by July 2018, Myriad had completed the acquisitions of Assurex Health, Inc. and its product GeneSight, as well as Counsyl, Inc. and its product ForeSight. Myriad touted the significant growth potential of acquiring these businesses and their products. However, Myriad failed to disclose that its GeneSight product lacked sufficient evidence to support its purported benefits, causing the product to come under question by the FDA. Myriad also neglected to inform investors that acquiring Counsyl’s product ForeSight could incur risk of suffering from lower reimbursements, which could materially impact Myriad’s revenue. Then, on August 13, 2019, Myriad announced its fiscal fourth quarter and full year 2019 results, revealing that lower reimbursements for Foresight had caused Myriad to fall short of revenue expectations and that the FDA had requested changes to GeneSight and questioned the validity of its benefits. On this news, Myriad’s stock price fell $19.05, or almost 43%, to close at $25.50 per share. The stock has yet to recover.
Myriad Genetics, Inc. (MYGN) Shareholders Have Legal Options
Contact us to learn more:
Leo Kandinov
(800) 350-6003
[email protected]
Shareholder Information Form
Robbins Arroyo LLP is a nationally recognized leader in shareholder rights law. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits, and has helped its clients realize more than $1 billion of value for themselves and the companies in which they have invested. Click Here to receive free alerts from Stock Watch when companies engage in wrongdoing.
Attorney Advertising. Past results do not guarantee a similar outcome.
Contacts
Leo Kandinov
Robbins Arroyo LLP
5040 Shoreham Place
San Diego, CA 92122
[email protected]
(619) 525-3990 or Toll Free (800) 350-6003
www.robbinsarroyo.com
